Patent ID: 10398709

Abstract:
In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO3H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO3H,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.